Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Ofev
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2020
Details:
An analysis of the Phase III INBUILD® trial showed the proportion of patients with 10% or greater declines in lung function were lower in the Ofev® (nintedanib) group relative to placebo over 52 weeks.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Ofev
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020
Details:
The decision is based on the results of the INBUILD® trial, the first study to evaluate patients with a broad range of chronic fibrosing interstitial lung diseases (ILDs) and a progressive disease behavior.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Nintedanib Esylate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
Details:
The opinion is for the treatment of adults with other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
